Pharma News

National Cancer Institute begins phase II trial with Crolibulin in anaplastic thyroid cancer

EpiCept Corporation announced that the National Cancer Institute (NCI) has initiated a phase II trial with Crolibulin (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with Anaplastic Thyroid Cancer (ATC). Crolibulin is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumour activity in both preclinical and early clinical studies.

NIPER to organise 3-day symposium on DMPK in collaboration with Bristol Mayers Squibb

The National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab and Bristol Mayers Squibb are jointly organising an international symposium on ‘Drug Metabolism and Pharmacokinetics (DMPK)--Applications toward Drug Discovery and Development’ from February 11 to 13 at the NIPER premises.